Preliminary in vivo data has demonstrated that MIRV/bevacizumab combination can induce substantial tumor regression, including complete responses, in ovarian cancer xenografts.106 A subsequent Phase 1b clinical trial (NCT02606305) showed that MIRV/bevacizumab combination therapy is well tolerated in PROC, with lower incidence of myelosuppressive toxicities relative to conventional cytotoxic regimens.107 Additionally, MIRV/bevacizumab appeared to have a higher ORR in patients with moderate or high FRα expression than conventional treatment. The gene discussed is FOLR1; the disease is ovarian carcinoma.